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To delineate the binding site in the human immunoglobulin E (IgE) molecule to the Fee receptor on basophils and mast cells, we chemically 
synthesized a total of 71 peptide fragments within the sequence Ser’oo-Lys”7 m the human IgE molecule. The synthetic peptides were tested for 
their capacity to inhibit passive sensitization of human peripheral basophils with atopic patient’s serum containing the specific IgE against dust 
mites in vitro. It was found that a peptide fragment, Pro345-Ile’56. potently inhibited the passive sensitization. To clarify the minimal active core, 
various analogues, such as shortened, substituted (by Gly or Ala residue), omission and retro-sequence peptides, were synthesized and assayed. 
The results suggested that the sequence Pro345-Lys352 m the human IgE molecule would be an IgE binding site, and that a synthetic octapeptide. 
Pro’45-Phe-Asp-Leu-Phe-Ile-Arg-Lys35z, inhibited the passive sensitization, probably by occupying the FCE receptor sites on the cells. 
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1. INTRODUCTION 
Immunoglobulin E (IgE) mediates immediate hy- 
persensitization such as asthma, hay fever, food and 
drug allergies. IgE circulates in the blood and binds to 
the Fee-chain type I receptor (FcsRI) on the surfaces of 
mast cells and basophils [l]. Bridging the receptor- 
bound IgE by a specific multivalent antigen triggers 
secretion of chemical mediators uch as histamine, slow- 
reacting substance of anaphylaxis and platelet activat- 
ing factor, which are responsible for type I immediate 
hypersensitivity [2,3]. It was thought that, by binding to 
and blocking the FcERI, certain peptides including the 
binding site(s) would inhibit release of the chemical me- 
diators. Such an IgE receptor-binding peptide will be- 
come an anti-allergic agent for type I immediate hy- 
persensitivity [4]. 
Several approaches have been utilized to determine 
the binding site to the human Fc&RI. Studies with pro- 
teolytic peptide fragments of human IgE [5], as well as 
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conformational studies [6] after gentle heating have sug- 
gested that the binding site lies in the Fcr region, in 
particular, in the CH3 and CH4 domains. Recombinant 
Fc&-chain fragments within two-third of the CH2, and 
all of the CH3 and CH4 domains have blocked passive 
sensitization of human skin with IgE [7-91. Therefore, 
it has been suggested that the binding site would be 
located in the CH3 and/or CH4 domains. However, the 
exact binding sites remain unidentified. 
We previously reported that synthetic human IgE 
peptide fragments with inhibitory activity on passive 
cutaneous anaphylaxis (PCA) in rats were located 
within the sequences Ala329-Thr357 in the CH3 domain, 
and Arg419 -Alae3 in the junction between the CH3 and 
CH4 domains, and that these two regions might be 
responsible for binding of IgE to its receptor [lo]. How- 
ever, it has been suggested that the interaction between 
IgE and its receptor is relatively specific to species [l 11. 
In this study, the synthetic human IgE peptide frag- 
ments were tested for inhibitory activity of passive sen- 
sitization of human peripheral basophils with atopic 
patient’s serum (allergen specific human IgE) in vitro. 
On the other hand, it has recently been suggested that 
the FceRI-binding site on human IgE is located within 
the sequence Gln30’-Arg376 in the junction between the 
CH2 and CH3 domains [12]. To pinpoint the binding 
site more precisely, we continued the synthesis of pep- 
tide fragments within the sequence Ser300-Lys547 corre- 
sponding to the C-terminus in the human IgE molecule. 
This paper describes the inhibition of the passive sensi- 
tization by synthetic human IgE peptide fragments. 
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2. MATERIALS AND METHODS 
2. I. Peptide synthesis 
All peptides used were synthesized by the stepwise solid-phase 
method using Fmoc chemistry [12,131 as described previously [15,161. 
The purity of each peptide was confirmed by thin-layer chromatogra- 
phy, high-performance liquid chromatography, fast atom bombard- 
ment mass spectrometry, sequencing with a gas-phase microse- 
quencer, and amino acid analysis after hydrolyzing in constant-boiling 
HC1 at 110°C for 24 h. The sequences of compounds are shown in 
Tables I-IV. 
2.2. Inhibitory activrty of the synthetic peptides 
The ability of the synthesized peptides to passive sensitization of 
human peripheral basophils with allergen-specific human IgE in vitro 
was assayed by the method ofNakamura et al. [17]. A solution consist- 
ing of 120 mM NaCl, 5 mM KC], 0.03% human serum albumin, and 
25 mM Tris was adjusted to pH 7.6. This solution was used as a 
standard buffer for the assay. The passive sensitization was carried out 
according to the modified method of Pruzansky et al. [18]. Peripheral 
basophils (leukocyte fraction) were separated from whole blood ob- 
tained from healthy volunteers. The blood (50 ml) was mixed with 0.1 
M EDTA (4 ml) and 6% dextran/3% glucose in physiological saline 
(12.5 ml), and allowed to sediment at room temperature for 60 min. 
The upper layer was centrifuged at 1,200 rpm for 10 min. The precip- 
itate containing the leukocyte fraction was washed once with the 
standard buffer containing 4 mM EDTA, incubated with lactate 
buffer (pH 3.9) at 0°C for 5 min, washed twice with the standard buffer 
containing 4 mM EDTA and the cells were suspended in the standard 
buffer containing 4 mM EDTA and heparin (12.5 pg/ml). The cell 
concentration was adjusted to 1-2 x IO’ cells/ml. 
The peptide solution (0.1 ml) was added to this cell suspension (0.7 
ml) and incubated at 37°C for 30 min. Thereafter, 0.2 ml of the serum 
from an atopic patient sensitive to dust mites was added to the suspen- 
sion and the mixture was incubated at 37°C for 120 min. The cells were 
collected by centrifugation, and washed twice with the standard 
buffer. The cell suspension (2-8 x lo6 cells/ml) was prepared with the 
standard buffer containing 0.6 mM CaCl, and I mM MgC&. This cell 
suspension (0.7 ml) was incubated with dust mite extract (Andard- 
Mount Ltd.) as the allergen at 37°C for 45 mm. The mixture was then 
cooled in an ice-bath and centrifuged. The amount of histamine in the 
supernatant and precipitate was determined with an automated 
fluorometer (Technicon Ltd.) by the method of Siraganian [19]. The 
inhibitory rate of histamine release was evaluated by comparing the 
amount of histamine released from the cells in the presence of synthetic 
peptides with that of the control, in which the standard buffer contain- 
ing 4 mM EDTA and heparin (12.5 ,@ml) was added to the cells 
instead of the synthetic peptide solution. Three donors were used as 
each concentration consisted of 3 tubes per donor. 
3. RESULTS AND DISCUSSION 
In our previous paper [lo], we suggested that the 
synthetic human IgE peptide fragments which inhibited 
PCA in rats were located within the sequence Ala3’9- 
Thr357 in the CH3 domain and Arg4’9-Ala463 in the junc- 
tion between the CH3 and CH4 domains, and that they 
might be involved in binding of IgE to its receptor. On 
the other hand, Helm et al. recently suggested that the 
FcERI-binding site on human IgE was located within 
the sequence Gln30’-Arg376 in the junction between the 
CH2 and CH3 domains [12,20]. Therefore, we contin- 
ued the synthesis of the peptide fragments within the 
sequence Ser3m-Lys547 of the human IgE molecule to 
determine the exact site responsible for the IgE-FceRI 
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interaction. In the synthesis, the cysteine residues of the 
disulfide bridges in IgE [21]. which are assumed not to 
be involved in the binding between IgE and its receptor, 
were replaced by serine residues. The possible binding 
regions to the FceRI were predicted by secondary struc- 
ture predictions [22], scans for the hydrophilic [23] and 
hydrophobic residues [24], and the study of homologous 
sequences among immunoglobulins. We synthesized 
various peptides consisting of 4445 amino acid residues 
within the sequence 300-547 of human IgE. 
To delineate the binding site of human IgE to the 
FcERI on human basophils, human basophils were pas- 
sively sensitized with atopic patient’s serum in vitro [ 171, 
since the interaction between IgE and FcERI is rela- 
tively specific to species [l I]. The acid-treated periph- 
eral basophils of healthy volunteers were passively sen- 
sitized with the serum of atopic patient’s donor sensitive 
to dust mites. Histamine release from the cells was in- 
duced by the dust mite extract. A quantitative relation- 
ship was obtained between the percentage of histamine 
release and the concentration of its serum. The affinity 
of myeloma IgE to the FceRI was comparable to that 
of native IgE. Myeloma IgE did not recognize the dust 
mite extract, which was the antigen for the serum of 
atopic patient’s donor. In this test, human myeloma IgE 
inhibited the passive sensitization in a concentration- 
related manner at concentrations of 0.3-3 ,&ml (data 
not shown) [17]. Therefore, this passive sensitization 
method is capable of revealing whether tested peptides 
prevent the interaction between human IgE and its re- 
ceptor. 
Table I summarizes the results of the inhibitory activ- 
ity of the synthetic peptide fragments. Among them, 
peptide fragments with strong inhibitory activity were 
found in amino acid sequences 345-356 (compound 11) 
and 479496 (compound 26). Furthermore, compound 
26 inhibited non-specific histamine release [25] by a 
Ca”’ ionophore, A231 87, whereas compound 11 had no 
inhibitory activity for the non-specific histamine release 
(data not shown). The amino acid sequence 345-356 
(compound 11) was included in a human IgE-FceRI- 
binding region reported by Helm et al. [I 21, and located 
on the surface of a three-dimensional model [26] 
of human IgE. In our previous paper [lo], com- 
pound 11 (Pro345-Phe-Asp-Leu-Phe-Ile-Arg-Lys-Ser- 
Pro-Thr-Ile356) also inhibited the PCA reaction in rats. 
Thus, it was suggested that compound 11 is a possible 
IgE-FceRI-binding site, thus preventing the interac- 
tion between IgE and its receptor on human basophils. 
In order to determine the minimal active core, various 
analogues of compound 11 were prepared and assayed. 
Shortening the peptide chain of compound 11(345-356) 
one by one at its C-terminus gave compounds 4146 
(Table II). As the size of the peptide decreased, inhib- 
itory activity increased, peaking at compound 44 (3455 
352). Further shortening of the peptide chain decreased 
the potency. In contrast, the potency of compound 11 
Volume 319, number 3 FEBS LETTERS March 1993 
Table I 
Inhibition of passive sensitization with human IgE by synthetic human IgE peptide fragments in human peripheral basophils in vitro 
No. Compound 
1 (300-309)b SQKHWLSDRT 
2 (305-314) LSDRTYTSQT 
3 (3 13-322) QVTYQGHTFE 
4 (318-328) GHTFEDSTKK 
5 (321-332) FEDSTKKSADSP 
6 (329-348) ADSNPRGVSAYLSRPSPFDL 
7 (329-357) ADSNPRGVSAYLSRPSPFDLFIRKSPTIT 
8 (329-339) ADSNPRGVSA 
9 (333-344) PRGVSAYLSRPS 
10 (340-349) YLSRPSPFDL 
11 (345-356) PFDLFIRKSPTI 
12 (349-368) FIRKSPTITSLWDLAPSKGC 
13 (357-367) TSLWDLAPSKC 
14 (368-387) GTVNLTWSRASGKPVNHSTR 
15 (386399) KPVNHSTRKEEKQRNGTLTV 
16 (400-111) TSTLPVGTRDWI 
17 (4111125) IEGETYQSRVTHPHL' 
18 (417437) QSRVTHPHLPRALMRSTTKTS' 
19 (419463) RVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLA 
20 (434448) TKTSGPRAAPEVYAF 
21 (449463) ATPEWPGSRDKRTLA 
22 (454466) PGSRDKRTLASLIC 
23 (456-461) SRDKRT 
24 (466-480) IQNFMPEDISVQWLH 
25 (479489) LHNEVQLPDAR 
26 (479496) LHNEVQLPDARHSTTQPR 
27 (485-504) LPDARHSTTQPRKTKGSGFF 
28 (496505) RKTKGSGFFV 
29 (505-510) VFSRLE 
30 (510-519) EVTRAEWEQK 
31 (517-523) EQKDEFI 
32 (523-530) ISRAVHEA' 
33 (530-535) AASPSQ 
34 (531-547) ASPSQTVQRAVSVNPGK 
a Percent inhibition of histamine release at 1 x 10-j M. 
bThe positions of the synthetic peptide fragments are shown in parentheses. For the residual number, refer to [6]. 
’ Cys was replaced with Ser. 
d Percent inhibition of histamine release at 1 x 10m4 M. 
Inhibition (8) 
-3.5 
4.3 
-13.8 
-1.8 
15.6 
2.1 
2.4 
1.8 
8.9 
4.7 
39.7 
-5.7 
9.2 
-2.2 
2.4 
11.2 
8.1 
10.6 
26.9 
-1.1 
9.0 
0.4 
4.7 
12.3 
12.8d 
45.1 
-0.4 
6.3 
-0.7 
1.0 
-1.2 
11.9 
2.0 
7.1 
decreased when the same procedure was applied to its 
N-terminus. Furthermore, extension and shortening of 
the peptide chain of compound 44 at the N-terminus 
(compounds 47-52) removed the inhibitory activity, as 
shown in Table III. Therefore, we conclude that the 
octapeptide (Pro 345-Phe-Asp-Leu-Phe-Ile-Arg-Lys352, 
compound 44) is the active core of compound 11, in 
other words, a possible binding site of human IgE. 
In an attempt to determine the amino acid residue(s) 
essential for the inhibitory activity, various analogues, 
such as omission (compounds 53-60), substitution (by 
Ala or Gly residue, compounds 61-70), and retro-se- 
quence peptides (compound 71) were synthesized and 
assayed (Table IV). The potency of the omission ana- 
logues of compound 44 was very low relative to com- 
pound 44. In a series of single amino acid substitutions 
by Ala or Gly residues, their activity decreased. In addi- 
tion, the retro-sequence peptide of compound 44 (com- 
Table II 
Inhibition of passive sensitization with human IgE by compound 1 l- 
related peptides in human peripheral basophils in vitro 
No. Compound Inhibition (%) 
1 x 1O-4 M 1 x 1O-3 M 
35 RKSPTI _ 11.9 
36 IRKSPTI 6.9 
37 FIRKSPTI _ 5.0 
38 LFIRKSPTI _ 10.4 
39 DLFIRKSPTI _ 0.8 
40 FDLFIRKSPTI 1.0 
11 PFDLFIRKSPTI 2.4 39.7 
41 PFDLFIRKSPT 12.9 63.3 
42 PFDLFIRKSP 22.4 insoluble 
43 PFDLFIRKS 28.0 insoluble 
44 PFDLFIRK 11.0 78.7 
45 PFDLFIR 5.9 insoluble 
46 PFDLFI 10.6 
a Percent inhibition of histamine release. 
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Table III 
InhIbition of passive sensitization with human IgE by compound 44- 
related peptides in human peripheral basophils in vitro 
octapeptide, Pro345-Phe-Asp-Leu-Phe-Ile-Arg-Lys35’, in- 
hibited the histamine release from basophils, probably 
by occupying the Fcs receptor site on the cells. 
No. Compound Inhibition (%) 
1 x 1O-J M 1 x 10-j M 
47 PSPFDLFIRK 12.4 
48 SPFDLFIRK 10.7 
44 PFDLFIRK 11.0 78.7 
49 FDLFIRK 31.4 
50 DLFIRK _ 9.8 
51 LFIRK _ 12.8 
52 FIRK _ 13.2 
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d Percent inhibitlon of histamine release. 
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